June 4, 2013Fitch, Even, Tabin and Flannery LLP has been recognized as a leading intellectual property law firm in Illinois in the 2013 edition of Chambers USA: America’s Leading Lawyers for Business, a prestigious research-based directory and one of the most widely cited referral sources for legal services in the United States.
In addition, Timothy P. Maloney, the firm’s Managing Partner, was singled out by Chambers as a leader in the field of intellectual property law in Illinois. Tim’s practice entails all aspects of intellectual property enforcement and defense, with an emphasis on representing plaintiffs in patent litigation, often multi-party complex litigation. He is an established trial lawyer with a solid track record in numerous jury and bench trials, including cases involving patent, trade secret, antitrust, trademark, unfair competition, and professional malpractice matters. Tim has also successfully argued several cases before the U.S. Court of Appeals for the Federal Circuit. In addition, he provides counsel on mergers and acquisitions, technology licenses, patent portfolio sales, and other business transactions.
Published annually by London-based Chambers & Partners, Chambers USA determines its rankings through independent research and confidential, in-depth interviews with clients and attorneys. Inclusion in the guide is based solely on the findings of the Chambers research team. Criteria used includes technical legal ability, professional conduct, client service, commercial astuteness, diligence, commitment and other qualities most valued by clients.
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more